#long-acting injectables

Some People With HIV Still Experience Treatment Challenges

Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.

As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.

A major plus of the implant is that it can be easily removed if necessary.

Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.

Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.

Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.

A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.

The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.

Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.

The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.

Given every four weeks, combo injections of cabotegravir and rilpivirine will likely face an FDA decision by early 2020.

Periodic infusions of long-acting HIV antibodies may eventually become a new way of treating the virus.